AU
UK
CA
NZ
IND
US
Last update at 2026-06-19T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | 0.06M | -0.01482M | - | - | - |
| Minority interest | - | - | - | - | - |
| Net income | 0.06M | -0.01482M | - | - | - |
| Selling general administrative | - | - | - | - | - |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | - | - | - | - | - |
| Reconciled depreciation | - | - | - | - | - |
| Ebit | - | -0.18271M | - | - | - |
| Ebitda | 0.06M | -0.01482M | - | - | - |
| Depreciation and amortization | - | 0.17M | 0.23M | 0.24M | 0.21M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -0.00730M | -0.01482M | - | - | - |
| Other operating expenses | 0.00730M | 0.01M | - | - | - |
| Interest expense | - | - | - | - | - |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | - | - |
| Net interest income | - | - | - | - | - |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | - | -0.16789M | - | - | - |
| Total revenue | - | - | - | - | - |
| Total operating expenses | 0.00730M | 0.01M | - | - | - |
| Cost of revenue | - | - | - | - | - |
| Total other income expense net | 0.06M | -0.00001M | - | - | - |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | - | - | - | - |
| Net income applicable to common shares | - | - | - | - | - |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | - | - | - | - | - |
| Intangible assets | - | - | - | - | - |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | - |
| Total liab | - | - | - | - | - |
| Total stockholder equity | - | - | - | - | - |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | - | - | - | - | - |
| Common stock | - | - | - | - | - |
| Capital stock | - | - | - | - | - |
| Retained earnings | - | - | - | - | - |
| Other liab | - | - | - | - | - |
| Good will | - | - | - | - | - |
| Other assets | - | - | - | - | - |
| Cash | - | - | - | - | - |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | - | - | - | - | - |
| Current deferred revenue | - | - | - | - | - |
| Net debt | - | - | - | - | - |
| Short term debt | - | - | - | - | - |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | - | - | - | - | - |
| Property plant equipment | - | - | - | - | - |
| Total current assets | - | - | - | - | - |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | - | - |
| Short term investments | - | - | - | - | - |
| Net receivables | - | - | - | - | - |
| Long term debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts payable | - | - | - | - | - |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | - | - | - |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | - | - | - | - | - |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2024-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 |
| Investments | - | -0.11786M | - | - | - |
| Change to liabilities | - | -2.20708M | 1.35M | 0.45M | 0.94M |
| Total cashflows from investing activities | - | -0.11786M | -2.70530M | -0.26892M | -0.43935M |
| Net borrowings | - | -1.13445M | 3.86M | 2.76M | 9.12M |
| Total cash from financing activities | 0.01M | 2.95M | 2.67M | 6.31M | 8.99M |
| Change to operating activities | - | 3.22M | 0.60M | -0.06857M | -0.42107M |
| Net income | -0.01482M | 2.06M | 5.49M | -8.21568M | -16.80423M |
| Change in cash | - | 1.54M | 3.04M | -1.67816M | 0.33M |
| Begin period cash flow | 6.91M | 5.37M | 2.33M | 4.01M | 3.68M |
| End period cash flow | - | 6.91M | 5.37M | 2.33M | 4.01M |
| Total cash from operating activities | -0.01482M | -0.53499M | 3.03M | -7.72998M | -8.31717M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | - | 1.03M | 0.67M | 0.99M | 1.11M |
| Other cashflows from investing activities | - | - | - | - | - |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | 0.15M | -1.02378M | 0.44M | -0.77053M |
| Change to account receivables | - | -6.69174M | -1.73537M | -1.93206M | -0.05466M |
| Sale purchase of stock | - | 2.74M | 2.42M | 2.42M | 2.42M |
| Other cashflows from financing activities | 0.01M | 0.21M | 0.25M | 14.85M | 9.79M |
| Change to netincome | - | 1.90M | -2.32989M | 0.60M | 7.67M |
| Capital expenditures | 0.00000M | 0.12M | 2.71M | 0.27M | 0.44M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.01M | -5.52709M | -0.80537M | -1.10548M | -0.30201M |
| Stock based compensation | - | 0.79M | -0.11911M | 0.02M | - |
| Other non cash items | -0.01482M | 1.26M | 0.37M | 0.58M | 7.67M |
| Free cash flow | -0.01482M | -0.65285M | 0.32M | -7.99890M | -8.75653M |
Sector: Financial Services Industry: Shell Companies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AOXG Aoxing Pharmaceutical Company Inc |
- -% | 0.004 | - | - | 0.05 | 0.07 | 0.05 | 0.73 |
| CLUS CLUS |
- -% | 200.00 | - | - | 0.09 | 0.92 | 0.72 | -8.9658 |
| SVMB SavMobi Technology Inc. |
- -% | 1.00 | - | - | 239.23 | - | 363.28 | -319.6012 |
| PBAJ Petro Usa Inc |
- -% | 0.0005 | - | - | - | - | -9042.9978 | |
| ALSAF ALSAF |
- -% | 15.40 | - | - | - | 0.85 |
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is based in Foster City, California.
1098 Foster City Blvd, Foster City, CA, United States, 94404
| Name | Title | Year Born |
|---|---|---|
| Mr. Zhenjiang Yue | Chairman and Chief Exec. Officer | 1959 |
| Mr. Guoan Zhang | CFO, Chief Accounting Officer & Sr. VP of Fin. | 1970 |
| Ms. Yunlan Tang | Chief Engineer | 1946 |
| Wei Zhang | Corp. Sec. | NA |
| Ms. Guirong Zhou | Pres of R&D | 1954 |
| Ms. Hongyue Hao | Vice Gen. Mang. of Financial Operations | 1971 |
| Mr. Zhenjiang Yue | Chairman and Chief Executive Officer | 1959 |
| Mr. Guoan Zhang | Chief Accounting Officer & Senior VP of Finance | 1970 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...